Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFATC1 | O95644 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | RHEB | Q15382 | 5/20 | 0.40 |
| ▸ | AXL | P30530 | 2/20 | 0.39 |
| ▸ | PRKCI | P41743 | 2/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.37 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30554075 | 1.00 | NFATC1 (0.44) | NFATC1GSK3BDYRK1ABRD4RHEB | |
| SCHEMBL30578263 | 0.74 | BRD4 (0.41) | NFATC1GSK3BDYRK1ABRD4IGF1R | |
| SCHEMBL2628872 | 0.74 | BRD4 (0.41) | NFATC1GSK3BDYRK1ABRD4IGF1R | |
| SCHEMBL2619221 | 0.74 | BRD4 (0.45) | NFATC1GSK3BDYRK1ABRD4AXL | |
| SCHEMBL23148015 | 0.74 | NUDT1 (0.43) | NFATC1GSK3BDYRK1ABRD4IGF1R | |
| SCHEMBL23937722 | 0.74 | BRD4 (0.45) | NFATC1GSK3BDYRK1ABRD4IGF1R | |
| SCHEMBL30368744 | 0.74 | BRD4 (0.45) | NFATC1GSK3BDYRK1ABRD4IGF1R | |
| SCHEMBL529739 | 0.74 | AHR (0.52) | NFATC1GSK3BDYRK1ABRD4RHEB | |
| SCHEMBL15926855 | 0.74 | BRD4 (0.41) | NFATC1GSK3BDYRK1ABRD4IGF1R | |
| SCHEMBL25336148 | 0.69 | BRD4 (0.39) | NFATC1GSK3BDYRK1ABRD4AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005016878-A2 | METHODS FOR THE PREPARATION OF 5-FLUORO-PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | claimed |
| CN-118271324-A | Preparation method of poncirtinib phosphate | 苏州源新科技产业园有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20230348380-A1 | Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348380-A1 | Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230250096-A1 | SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-10 | — | — | US | disclosed |
| CN-106459042-A | Anti-fibrotic pyridinones | 英特穆恩公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-105530932-A | Primary carboxamides as BIK inhibitors | ABBVIE INC | 2016-04-27 | — | — | CN | disclosed |
| CN-104822687-A | Anti-fibrotic pyridinones | INTERMUNE INC | 2015-08-05 | — | — | CN | disclosed |
| EP-2794605-A1 | 2, 4-DIAMINE-PYRIMIDINE DERIVATIVE AS SERINE/THREONINE KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-29 | — | — | EP | disclosed |
| US-8815877-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| WO-2009118175-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2009-10-01 | — | — | WO | disclosed |
| EP-2105164-A1 | Novel P2X7R antagonists and their use | Affectis Pharmaceuticals AG (DE) | 2009-09-30 | — | — | EP | disclosed |
| WO-2009007839-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING DRY EYE DISORDERS | PFIZER INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| EP-1734967-A2 | PYRROLO [2,3-D] PYRIMIDINE COMPOUNDS FOR TREATING TRANSPLANT REJECTION | Pfizer Products Incorporated (US) | 2006-12-27 | — | — | EP | disclosed |
| EP-1572213-A1 | METHOD OF TREATMENT OF TRANSPLANT REJECTION | Pfizer Products Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2005060972-A2 | PYRROLO [2,3-D] PYRIMIDINE COMPOUNDS FOR TREATING TRANSPLANT REJECTION | PFIZER PRODUCTS INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005016878-A2 | METHODS FOR THE PREPARATION OF 5-FLUORO-PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| WO-2004047843-A1 | METHOD OF TREATMENT OF TRANSPLANT REJECTION | PFIZER PRODUCTS INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| EP-1235830-A2 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | Pfizer Products Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001042246-A2 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348380-A1 | Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | TOP2A, PAICS, TOP1 | NFATC1 1309/4885GSK3B 3007/4885DYRK1A 4066/4885 |
| US-20230250096-A1 | SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES | MLLT1, BMI1, MEN1 | NFATC1 537/4885GSK3B 2246/4885DYRK1A 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.